RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice TargetHot
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $810 to $913.
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $810 to $913.